October 26, 2011
CONTACT: Karen Kreeger
Lab-Made Skin Cells Will Aid Transplantation, Cancer, Drug Discovery Research, Say Penn Scientists
PHILADELPHIA - The pigmented cells called melanocytes aren't just for making freckles and tans. Melanocytes absorb ultraviolet light, protecting the skin from the harmful effects of the sun. They also are the cells that go haywire in melanoma, as well as in more common conditions as vitiligo and albinism.
Naturally, researchers would love to study melanocytes in the laboratory. There's just one problem -- melanocytes from adult skin don't grow very well in the lab. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found a way to create melanocytes from mouse tail cells using embryonic stem cell-like intermediates called inducible pluripotent (iPS) cells.
Xiaowei Xu, MD, PhD, associate professor of Pathology and Laboratory Medicine, is senior author the study, which appears online in the Journal of Investigative Dermatology ahead of the December print issue. Xu and his team converted mouse tail-tip fibroblasts into iPS cells using four genes, which were first described by Shinya Yamanaka in 2006, producing pluripotent cells similar to embryonic stem cells, but without the concomitant ethical issues.
According to Xu, these lab-made melanocytes promise benefits in areas from tissue transplantation to drug discovery. "This method really has lots of clinical implications," says Xu. "We are not quite there yet, but this is an early step."
For example, by collecting a tissue sample from patients with, say, vitiligo, and converting it to iPS cells, researchers can study what goes wrong as those cells differentiate into melanocytes. Or, they can study the development and possible treatment of melanoma.
Xu's new study is the first to report creating melanocytes from iPS cells in mice, and builds on his previous work. Xu's lab was involved in the first study to work out the conditions for differentiating human embryonic stem cells to melanocytes in 2006. Earlier this year, a Japanese team became the first to differentiate human iPS cells to melanocytes.
Transformation of Cells
According to Xu, the growth factor cocktail used in the present study differs somewhat from the formulation his lab worked out several years ago for human embryonic stem cells. Among other things, it works in the absence of the growth factor Wnt3a and the carcinogen TPA, both of which are required for human melanocyte differentiation. TPA, especially, could be problematic for possible cell-based therapies, in that it is tumorigenic. It remains to be seen, however, whether human iPS cells can also be differentiated in the absence of this compound, Xu notes.
His study's implementation of piggyBac in creating the iPS cells (a technique first published by Canadian researchers in 2009) could possibly extend the technique's clinical value, he adds. Unlike viruses, which insert their genetic cargo into the host genome, thereby raising concerns of genetic alterations in the infected cells, piggyBac delivers genes without permanently altering the host genome.
Other authors include Penn researchers Ruifeng Yang, Min Jiang, Suresh Kumar, and Ted Xu, as well as Fei Wang of the University of Illinois, Urbana-Champaign and Leihong Xiang of Fudan University, Shanghai.
The study was funded by the National Institute of Arthritis and Musculoskeletal and Skin.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.